Nishina T, et al. - Researchers undertook this phase 1, open-label, multicenter, single-arm, dose-escalation study to determine the safety, pharmacokinetics (PK), and pharmacodynamics of erdafitinib (JNJ-42756493) and to assess the recommended phase 2 dose in Japanese patients with advanced or refractory solid tumors. As per the safety and PK data, researchers recommended the 10 mg 7 days-on/7 days-off regimen as phase 2 dose in this study. In Japanese patients with advanced or refractory solid tumors, erdafitinib was well tolerated.